

Jack Hirsh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10785688/publications.pdf>

Version: 2024-02-01

278
papers

50,643
citations

1697

104
h-index

1381

222
g-index

282
all docs

282
docs citations

282
times ranked

19013
citing authors

#	ARTICLE	IF	CITATIONS
1	Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin. <i>New England Journal of Medicine</i> , 1995, 332, 1330-1336.	13.9	2,664
2	Pharmacology and Management of the Vitamin K Antagonists. <i>Chest</i> , 2008, 133, 160S-198S.	0.4	1,926
3	Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer. <i>Thrombosis and Haemostasis</i> , 2000, 83, 416-420.	1.8	1,417
4	Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. <i>Chest</i> , 2001, 119, 64S-94S.	0.4	1,275
5	A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , 1996, 334, 677-681.	13.9	1,157
6	The Pharmacology and Management of the Vitamin K Antagonists. <i>Chest</i> , 2004, 126, 204S-233S.	0.4	1,092
7	A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 1999, 340, 901-907.	13.9	1,052
8	Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events. <i>Circulation</i> , 2002, 105, 1650-1655.	1.6	1,040
9	Heparin. <i>New England Journal of Medicine</i> , 1991, 324, 1565-1574.	13.9	996
10	Heparin and Low-Molecular-Weight Heparin. <i>Chest</i> , 2004, 126, 188S-203S.	0.4	896
11	Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range. <i>Chest</i> , 2001, 119, 8S-21S.	0.4	862
12	Oral Anticoagulants. <i>Chest</i> , 1998, 114, 445S-469S.	0.4	856
13	A Comparison of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody Syndrome. <i>New England Journal of Medicine</i> , 2003, 349, 1133-1138.	13.9	845
14	Management of Anticoagulation before and after Elective Surgery. <i>New England Journal of Medicine</i> , 1997, 336, 1506-1511.	13.9	781
15	Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy. <i>Chest</i> , 2008, 133, 844S-886S.	0.4	744
16	Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein Thrombosis. <i>New England Journal of Medicine</i> , 1986, 315, 1109-1114.	13.9	730
17	Accuracy of clinical assessment of deep-vein thrombosis. <i>Lancet</i> , The, 1995, 345, 1326-1330.	6.3	705
18	Heparin and Low-Molecular-Weight Heparin. <i>Chest</i> , 1998, 114, 489S-510S.	0.4	679

#	ARTICLE	IF	CITATIONS
19	Parenteral Anticoagulants. Chest, 2008, 133, 141S-159S.	0.4	674
20	A Prospective Study of the Value of Monitoring Heparin Treatment with the Activated Partial Thromboplastin Time. New England Journal of Medicine, 1972, 287, 324-327.	13.9	652
21	Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis. New England Journal of Medicine, 1979, 301, 855-858.	13.9	631
22	Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?. Journal of Thoracic and Cardiovascular Surgery, 2004, 128, 211-219.	0.4	624
23	American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation, 2003, 107, 1692-1711.	1.6	593
24	Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects. Chest, 2004, 126, 234S-264S.	0.4	578
25	Platelet-Active Drugs. Chest, 2001, 119, 39S-63S.	0.4	569
26	Oral Anticoagulant Drugs. New England Journal of Medicine, 1991, 324, 1865-1875.	13.9	566
27	Management of Deep Vein Thrombosis and Pulmonary Embolism. Circulation, 1996, 93, 2212-2245.	1.6	553
28	A Randomized Controlled Trial of a Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip Surgery. New England Journal of Medicine, 1986, 315, 925-929.	13.9	529
29	Managing Oral Anticoagulant Therapy. Chest, 2001, 119, 22S-38S.	0.4	525
30	Heparin for 5 Days as Compared with 10 Days in the Initial Treatment of Proximal Venous Thrombosis. New England Journal of Medicine, 1990, 322, 1260-1264.	13.9	524
31	A Comparison of Aspirin with Placebo in Patients Treated with Warfarin after Heart-Valve Replacement. New England Journal of Medicine, 1993, 329, 524-529.	13.9	521
32	Use of Antithrombotic Agents During Pregnancy. Chest, 2004, 126, 627S-644S.	0.4	498
33	Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment. New England Journal of Medicine, 2010, 363, 1704-1714.	13.9	497
34	Antiplatelet Drugs. Chest, 2008, 133, 199S-233S.	0.4	478
35	Adjusted Subcutaneous Heparin versus Warfarin Sodium in the Long-Term Treatment of Venous Thrombosis. New England Journal of Medicine, 1982, 306, 189-194.	13.9	477
36	Guide to Anticoagulant Therapy: Heparin. Circulation, 2001, 103, 2994-3018.	1.6	451

#	ARTICLE	IF	CITATIONS
37	Small Subcutaneous Doses of Heparin in Prevention of Venous Thrombosis. <i>New England Journal of Medicine</i> , 1973, 288, 545-551.	13.9	442
38	The Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast Cancer. <i>New England Journal of Medicine</i> , 1988, 318, 404-407.	13.9	421
39	Safety of Withholding Heparin in Pregnant Women with a History of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2000, 343, 1439-1444.	13.9	409
40	Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety. <i>Chest</i> , 1995, 108, 258S-275S.	0.4	396
41	Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. <i>American Journal of Medicine</i> , 1996, 100, 269-277.	0.6	370
42	Diagnostic Value of Ventilation-Perfusion Lung Scanning in Patients with Suspected Pulmonary Embolism. <i>Chest</i> , 1985, 88, 819-828.	0.4	357
43	Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , 1995, 74, 606-611.	1.8	351
44	Comparison of High-Dose with Low-Dose Subcutaneous Heparin to Prevent Left Ventricular Mural Thrombosis in Patients with Acute Transmural Anterior Myocardial Infarction. <i>New England Journal of Medicine</i> , 1989, 320, 352-357.	13.9	338
45	Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 166-181.	1.0	334
46	Antiplatelet Drugs. <i>Chest</i> , 2012, 141, e89S-e119S.	0.4	318
47	Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. <i>BMJ: British Medical Journal</i> , 2011, 342, d3036-d3036. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy ¹¹ The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1633-1652.	2.4	315
48	Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety. <i>Chest</i> , 1992, 102, 337S-351S.	1.2	314
49	Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety. <i>Chest</i> , 1992, 102, 337S-351S.	0.4	305
50	A Randomized Trial of a Single Bolus Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Acute Pulmonary Embolism. <i>Chest</i> , 1990, 98, 1473-1479.	0.4	304
51	Use of Antithrombotic Agents During Pregnancy. <i>Chest</i> , 2001, 119, 122S-131S.	0.4	297
52	Executive Summary. <i>Chest</i> , 2008, 133, 71S-109S.	0.4	291
53	An Improved Definition of Immune Heparin-Induced Thrombocytopenia in Postoperative Orthopedic Patients. <i>Archives of Internal Medicine</i> , 2003, 163, 2518.	4.3	287
54	RANDOMISED COMPARISON OF TWO INTENSITIES OF ORAL ANTICOAGULANT THERAPY AFTER TISSUE HEART VALVE REPLACEMENT. <i>Lancet, The</i> , 1988, 331, 1242-1245.	6.3	282

#	ARTICLE	IF	CITATIONS
55	Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. <i>New England Journal of Medicine</i> , 2016, 375, 1937-1945.	13.9	278
56	Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , 2008, 133, 110S-112S.	0.4	270
57	The Vexing Problem of Guidelines and Conflict of Interest: A Potential Solution. <i>Annals of Internal Medicine</i> , 2010, 152, 738.	2.0	268
58	Use of Antithrombotic Agents During Pregnancy. <i>Chest</i> , 1995, 108, 305S-311S.	0.4	264
59	Oral Anticoagulants. <i>Chest</i> , 1995, 108, 231S-246S.	0.4	260
60	New Antithrombotic Drugs. <i>Chest</i> , 2008, 133, 234S-256S.	0.4	235
61	Activated Partial Thromboplastin Time and Outcome After Thrombolytic Therapy for Acute Myocardial Infarction. <i>Circulation</i> , 1996, 93, 870-878.	1.6	232
62	Prevention and Treatment of Postphlebotic Syndrome. <i>Archives of Internal Medicine</i> , 2001, 161, 2105.	4.3	230
63	Characterization of the stress-inducing effects of homocysteine. <i>Biochemical Journal</i> , 1998, 332, 213-221.	1.7	221
64	Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular-Weight Heparin for Acute Treatment of Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 935.	3.8	219
65	Heparin Binding to Plasma Proteins, an Important Mechanism for Heparin Resistance. <i>Thrombosis and Haemostasis</i> , 1992, 67, 639-643.	1.8	216
66	Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines. <i>Chest</i> , 2012, 141, 53S-70S.	0.4	213
67	A Comparison of the Safety and Efficacy of Oral Anticoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy. <i>Thrombosis and Haemostasis</i> , 2000, 84, 805-810.	1.8	208
68	A Novel and Rapid Whole-Blood Assay for D-Dimer in Patients With Clinically Suspected Deep Vein Thrombosis. <i>Circulation</i> , 1995, 91, 2184-2187.	1.6	203
69	Beyond Unfractionated Heparin and Warfarin. <i>Circulation</i> , 2007, 116, 552-560.	1.6	202
70	American Association of Orthopedic Surgeons and American College of Chest Physicians Guidelines for Venous Thromboembolism Prevention in Hip and Knee Arthroplasty Differ. <i>Chest</i> , 2009, 135, 513-520.	0.4	200
71	Combined Use of Leg Scanning and Impedance Plethysmography in Suspected Venous Thrombosis. <i>New England Journal of Medicine</i> , 1977, 296, 1497-1500.	13.9	192
72	Risks to the Fetus of Anticoagulant Therapy During Pregnancy. <i>Thrombosis and Haemostasis</i> , 1989, 61, 197-203.	1.8	189

#	ARTICLE	IF	CITATIONS
73	Treatment of Heparin-Induced Thrombocytopenia. Archives of Internal Medicine, 2004, 164, 361.	4.3	184
74	Management of Suspected Deep Venous Thrombosis in Outpatients by Using Clinical Assessment and D-dimer Testing. Annals of Internal Medicine, 2001, 135, 108.	2.0	179
75	Assessment of Outpatient Treatment of Deep-Vein Thrombosis With Low-Molecular-Weight Heparin. Archives of Internal Medicine, 1998, 158, 2001.	4.3	178
76	DOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKE. Lancet, The, 1987, 329, 523-526.	6.3	177
77	Platelet-Active Drugs. Chest, 1998, 114, 470S-488S.	0.4	177
78	Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet, The, 2000, 356, 1551-1553.	6.3	175
79	A Randomized Trial Comparing 5-mg and 10-mg Warfarin Loading Doses. Archives of Internal Medicine, 1999, 159, 46.	4.3	167
80	Cost Effectiveness of Clinical Diagnosis, Venography, and Noninvasive Testing in Patients with Symptomatic Deep-Vein Thrombosis. New England Journal of Medicine, 1981, 304, 1561-1567.	13.9	163
81	A Histomorphometric Comparison of the Effects of Heparin and Low-Molecular-Weight Heparin on Cancellous Bone in Rats. Blood, 1997, 89, 3236-3242.	0.6	163
82	Approach to Outcome Measurement in the Prevention of Thrombosis in Surgical and Medical Patients. Chest, 2012, 141, e185S-e194S.	0.4	161
83	How we diagnose and treat deep vein thrombosis. Blood, 2002, 99, 3102-3110.	0.6	159
84	The Sixth (2000) ACCP Guidelines for Antithrombotic Therapy for Prevention and Treatment of Thrombosis. Chest, 2001, 119, 1S-2S.	0.4	155
85	New anticoagulants. Blood, 2005, 105, 453-463.	0.6	155
86	New Anticoagulant Drugs. Chest, 2001, 119, 95S-107S.	0.4	153
87	Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin. Thrombosis and Haemostasis, 1994, 71, 300-304.	1.8	150
88	Hemorrhagic Complications of Anticoagulant Treatment. Chest, 1995, 108, 276S-290S.	0.4	145
89	Congenital antithrombin III deficiency. American Journal of Medicine, 1989, 87, S34-S38.	0.6	144
90	New Anticoagulant Drugs. Chest, 2004, 126, 265S-286S.	0.4	142

#	ARTICLE	IF	CITATIONS
91	Elevated Platelet-Associated IgG in the Thrombocytopenia of Septicemia. <i>New England Journal of Medicine</i> , 1979, 300, 760-764.	13.9	141
92	Monitoring unfractionated heparin with the aPTT: Time for a fresh look. <i>Thrombosis and Haemostasis</i> , 2006, 96, 547-552.	1.8	141
93	Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease. <i>American Journal of Medicine</i> , 2011, 124, 621-629.	0.6	134
94	Fish Oils and Low-Molecular-Weight Heparin for the Reduction of Restenosis After Percutaneous Transluminal Coronary Angioplasty. <i>Circulation</i> , 1996, 94, 1553-1560.	1.6	133
95	Controversies in Timing of the First Dose of Anticoagulant Prophylaxis Against Venous Thromboembolism After Major Orthopedic Surgery. <i>Chest</i> , 2003, 124, 379S-385S.	0.4	130
96	Temporal Trends in Prevention of Venous Thromboembolism Following Primary Total Hip or Knee Arthroplasty 1996-2001. <i>Chest</i> , 2003, 124, 349S-356S.	0.4	124
97	Hemorrhagic Complications of Long-term Anticoagulant Therapy. <i>Chest</i> , 1989, 95, 26S-36S.	0.4	123
98	The International Normalized Ratio. <i>Archives of Internal Medicine</i> , 1994, 154, 282.	4.3	122
99	Heparin-Induced Skin Lesions and Other Unusual Sequelae of the Heparin-Induced Thrombocytopenia Syndrome. <i>Chest</i> , 2005, 127, 1857-1861.	0.4	121
100	Oral Anticoagulation Treatment in the Elderly. <i>Archives of Internal Medicine</i> , 2000, 160, 470.	4.3	119
101	Is Impaired Renal Function a Contraindication to the Use of Low-Molecular-Weight Heparin?. <i>Archives of Internal Medicine</i> , 2002, 162, 2605.	4.3	117
102	Hemorrhagic Complications of Anticoagulant Treatment. <i>Chest</i> , 1992, 102, 352S-363S.	0.4	115
103	New antithrombotic agents. <i>Lancet</i> , The, 1999, 353, 1431-1436.	6.3	111
104	Use of Antithrombotic Agents During Pregnancy. <i>Chest</i> , 1998, 114, 524S-530S.	0.4	108
105	Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 566.	3.0	106
106	A Comparison of General Anesthesia and Regional Anesthesia as a Risk Factor for Deep Vein Thrombosis Following Hip Surgery: A Critical Review. <i>Thrombosis and Haemostasis</i> , 1990, 64, 497-500.	1.8	106
107	The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro. <i>Thrombosis and Haemostasis</i> , 1998, 80, 413-417.	1.8	100
108	Hemorrhagic Complications of Anticoagulant Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 1986, 12, 39-57.	1.5	97

#	ARTICLE	IF	CITATIONS
109	A Novel Whole Blood Capillary Technic for Measuring the Prothrombin Time. American Journal of Clinical Pathology, 1987, 88, 442-446.	0.4	97
110	Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin. Circulation, 2003, 107, 2884-2888.	1.6	97
111	Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins. Thrombosis and Haemostasis, 1993, 70, 625-630.	1.8	97
112	Platelet-Inhibiting Drugs in the Prevention of Clinical Thrombotic Disease. New England Journal of Medicine, 1975, 293, 1174-1178.	13.9	96
113	Current anticoagulant therapyâ€™s unmet clinical needs. Thrombosis Research, 2003, 109, S1-S8.	0.8	93
114	Randomized Comparison of Direct Thrombin Inhibition Versus Heparin in Conjunction With Fibrolytic Therapy for Acute Myocardial Infarction: Results From the GUSTO-IIb Trial. Journal of the American College of Cardiology, 1998, 31, 1493-1498.	1.2	92
115	Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. American Journal of Cardiology, 1991, 67, 3-11.	0.7	91
116	Optimal Therapeutic Range for Oral Anticoagulants. Chest, 1989, 95, 5S-11S.	0.4	90
117	Hemorrhagic Complications of Thrombolytic Therapy in the Treatment of Myocardial Infarction and Venous Thromboembolism. Chest, 1995, 108, 291S-301S.	0.4	89
118	Low-Molecular-Weight Heparin. Circulation, 1998, 98, 1575-1582.	1.6	89
119	Prevention of venous thrombosis by intermittent sequential calf compression in patients with intracranial disease. Thrombosis Research, 1979, 15, 611-616.	0.8	84
120	Clinical experts or methodologists to write clinical guidelines?. Lancet, The, 2009, 374, 273-275.	6.3	83
121	Aspirin and Other Platelet-Active Drugs. Chest, 1995, 108, 247S-257S.	0.4	80
122	Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 766-780.	3.3	80
123	â€™Therapeutic Rangeâ€™ for Oral Anticoagulant Therapy. Chest, 1986, 89, 11S-15S.	0.4	79
124	Clinical features and diagnosis of venous thrombosis. Journal of the American College of Cardiology, 1986, 8, 114B-127B.	1.2	78
125	Recurrent Venous Thrombosis and Heparin Therapy. Archives of Internal Medicine, 1999, 159, 2029.	4.3	78
126	The Optimal Duration of Anticoagulant Therapy for Venous Thrombosis. New England Journal of Medicine, 1995, 332, 1710-1712.	13.9	76

#	ARTICLE	IF	CITATIONS
127	Induction of the Acute-Phase Reaction Increases Heparin-Binding Proteins in Plasma. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 1568-1574.	1.1	73
128	Use of a Fixed Activated Partial Thromboplastin Time Ratio to Establish a Therapeutic Range for Unfractionated Heparin. <i>Archives of Internal Medicine</i> , 2001, 161, 385.	4.3	72
129	Hemorrhagic Complications of Long-term Anticoagulant Therapy. <i>Chest</i> , 1986, 89, 16S-25S.	0.4	70
130	Epidemiology and pathogenesis of venous thrombosis. <i>Journal of the American College of Cardiology</i> , 1986, 8, 104B-113B.	1.2	69
131	A Histomorphometric Evaluation of Heparin-Induced Bone Loss After Discontinuation of Heparin Treatment in Rats. <i>Blood</i> , 1999, 93, 1231-1236.	0.6	69
132	Fibrinolytic Variables in Patients with Recurrent Venous Thrombosis: a Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , 2001, 85, 390-394.	1.8	69
133	Anticoagulants During Pregnancy. <i>Annual Review of Medicine</i> , 1989, 40, 79-86.	5.0	67
134	In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. <i>Thrombosis Research</i> , 2002, 107, 241-244.	0.8	66
135	The Diagnosis of Clinically Suspected Venous Thrombosis. <i>Clinics in Chest Medicine</i> , 1984, 5, 439-456.	0.8	65
136	Suboptimal Monitoring and Dosing of Unfractionated Heparin in Comparative Studies with Low-Molecular-Weight Heparin. <i>Annals of Internal Medicine</i> , 2003, 138, 720.	2.0	64
137	Effect of Nonspecific Binding to Plasma Proteins on the Antithrombin Activities of Unfractionated Heparin, Low-Molecular-Weight Heparin, and Dermatan Sulfate. <i>Circulation</i> , 1997, 95, 118-124.	1.6	64
138	Translational Success Stories. <i>Circulation Research</i> , 2012, 111, 920-929.	2.0	61
139	The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. <i>Transfusion</i> , 2012, 52, 1203-1212.	0.8	61
140	Bleeding and management of bleeding. <i>Country Review Ukraine</i> , 2006, 8, G38-G45.	0.8	60
141	Prevention of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 1976, 2, 232-290.	1.5	59
142	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 295-301.	1.0	59
143	The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: Influence of dosage regimens in rabbits. <i>Thrombosis Research</i> , 1985, 40, 769-777.	0.8	58
144	Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. <i>Thrombosis and Haemostasis</i> , 2014, 112, 918-923.	1.8	58

#	ARTICLE	IF	CITATIONS
145	Deep Vein Thrombosis: New Non-Invasive Diagnostic Tests. <i>Thrombosis and Haemostasis</i> , 1991, 66, 133-137.	1.8	57
146	An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition. <i>Thrombosis and Haemostasis</i> , 1993, 69, 231-235.	1.8	56
147	Mechanism of Action and Monitoring of Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 1986, 12, 1-11.	1.5	54
148	Use of Antithrombotic Agents During Pregnancy. <i>Chest</i> , 1992, 102, 385S-390S.	0.4	52
149	The Value of Plasma Calibrants in Correcting Coagulometer Effects on International Normalized Ratios: An International Multicenter Study. <i>American Journal of Clinical Pathology</i> , 1995, 103, 358-365.	0.4	51
150	Clinical Trials That Have Influenced the Treatment of Venous Thromboembolism: A Historical Perspective. <i>Annals of Internal Medicine</i> , 2001, 134, 409.	2.0	51
151	Guide to Anticoagulant Therapy: Heparin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, E9-9.	1.1	50
152	The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model. <i>Thrombosis and Haemostasis</i> , 1992, 68, 064-068.	1.8	50
153	Differences in inhibition of PGI ₂ production by aspirin in rabbit artery and vein segments. <i>Thrombosis Research</i> , 1980, 20, 447-460.	0.8	49
154	The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. <i>Translational Research</i> , 1997, 130, 649-655.	2.4	49
155	Low Molecular Weight Heparin. <i>Thrombosis and Haemostasis</i> , 1993, 70, 204-207.	1.8	49
156	Measurement of the Activated Partial Thromboplastin Time from a Capillary (fingerstick) Sample of Whole Blood: A New Method for Monitoring Heparin Therapy. <i>American Journal of Clinical Pathology</i> , 1991, 95, 222-227.	0.4	48
157	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. <i>Thrombosis and Haemostasis</i> , 2014, 111, 798-807.	1.8	48
158	Aspirin and Other Platelet-Active Drugs. <i>Chest</i> , 1992, 102, 327S-336S.	0.4	46
159	The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III. <i>Thrombosis Research</i> , 1980, 20, 391-403.	0.8	45
160	Use of Anticoagulants during Pregnancy. <i>Chest</i> , 1989, 95, 156S-160S.	0.4	45
161	Introduction: Antithrombotic Therapy—The Evolving Consensus. <i>Chest</i> , 1998, 114, 439S-440S.	0.4	45
162	New anticoagulants. <i>American Heart Journal</i> , 2001, 142, S3-S8.	1.2	45

#	ARTICLE	IF	CITATIONS
163	New antithrombotic agents’s insights from clinical trials. <i>Nature Reviews Cardiology</i> , 2010, 7, 498-509.	6.1	45
164	Peripheral Oxygen Saturation in Older Persons Wearing Nonmedical Face Masks in Community Settings. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2323.	3.8	45
165	The Incidence of Symptomatic Venous Thromboembolism After Enoxaparin Prophylaxis in Lower Extremity Arthroplasty. <i>Chest</i> , 1998, 114, 115S-118S.	0.4	44
166	Venous thromboembolism after long flights: are airlines to blame?. <i>Lancet</i> , 2001, 357, 1461-1462.	6.3	44
167	Hemorrhagic Complications of Thrombolytic Therapy in the Treatment of Myocardial Infarction and Venous Thromboembolism. <i>Chest</i> , 1989, 95, 88S-97S.	0.4	43
168	Rationale Behind the Development of Low Molecular Weight Heparin Derivatives. <i>Seminars in Thrombosis and Hemostasis</i> , 1985, 11, 13-16.	1.5	41
169	Prophylaxis of Venous Thromboembolism. <i>Chest</i> , 1986, 89, 374S-383S.	0.4	40
170	Hemorrhagic Complications of Thrombolytic Therapy in the Treatment of Myocardial Infarction and Venous Thromboembolism. <i>Chest</i> , 1992, 102, 364S-373S.	0.4	39
171	Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?. <i>British Journal of Haematology</i> , 2009, 146, 142-149.	1.2	39
172	Antithrombotic Agents in Coronary Artery Disease. <i>Chest</i> , 1992, 102, 456S-481S.	0.4	38
173	Reflecting on Eight Editions of the American College of Chest Physicians Antithrombotic Guidelines. <i>Chest</i> , 2008, 133, 1293-1295.	0.4	38
174	New Antithrombotics. <i>Chest</i> , 1995, 108, 471S-485S.	0.4	37
175	Optimal intensity and monitoring warfarin. <i>American Journal of Cardiology</i> , 1995, 75, 39B-42B.	0.7	36
176	Observations in anticoagulant and thrombolytic therapy in pulmonary embolism. <i>Progress in Cardiovascular Diseases</i> , 1975, 17, 335-343.	1.6	34
177	Risk of Haemorrhage Associated with Long Term Anticoagulant Therapy. <i>Drugs</i> , 1985, 30, 444-460.	4.9	34
178	Effects of Dermatan Sulfate and Heparin on Inhibition of Thrombus Growth in Vivo. <i>Annals of the New York Academy of Sciences</i> , 1989, 556, 304-312.	1.8	34
179	Low-molecular-weight heparin for the treatment of venous thromboembolism. <i>American Heart Journal</i> , 1998, 135, S336-S342.	1.2	33
180	Vasoflux, a New Anticoagulant With a Novel Mechanism of Action. <i>Circulation</i> , 1999, 99, 682-689.	1.6	33

#	ARTICLE	IF	CITATIONS
181	Diagnosis of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 1976, 2, 203-231.	1.5	32
182	The Binding of Unfractionated Heparin and Low Molecular Weight Heparin to Thrombin-Activated Human Endothelial Cells. <i>Thrombosis Research</i> , 1999, 96, 373-381.	0.8	32
183	A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 231-239.	1.0	32
184	New Antithrombotic Agents. <i>Chest</i> , 1998, 114, 715S-727S.	0.4	31
185	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. <i>TH Open</i> , 2017, 01, e139-e145.	0.7	31
186	Duration of Anticoagulant Therapy After First Episode of Venous Thrombosis in Patients With Inherited Thrombophilia. <i>Archives of Internal Medicine</i> , 1997, 157, 2174.	4.3	30
187	Direct thrombin inhibitors in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2012, 9, 402-414.	6.1	30
188	The Optimal Intensity of Oral Anticoagulant Therapy. <i>JAMA - Journal of the American Medical Association</i> , 1987, 258, 2723.	3.8	29
189	Substandard Monitoring of Warfarin in North America. <i>Archives of Internal Medicine</i> , 1992, 152, 257.	4.3	29
190	A Comparison of Lyophilized Artificially Depleted Plasmas and Lyophilized Plasmas From Patients Receiving Warfarin in Correcting for Coagulometer Effects on International Normalized Ratios. <i>American Journal of Clinical Pathology</i> , 1995, 103, 366-371.	0.4	29
191	Electrical Foot Stimulation: A Potential New Method of Deep Venous Thrombosis Prophylaxis. <i>Vascular</i> , 2010, 18, 20-27.	0.4	28
192	Role of phenotypic and genetic testing in managing clopidogrel therapy. <i>Blood</i> , 2014, 124, 689-699.	0.6	28
193	Ventilation-Perfusion Lung Scanning and the Diagnosis of Pulmonary Embolism: Improvement of Observer Agreement by the Use of a Lung Segment Reference Chart. <i>Thrombosis and Haemostasis</i> , 1992, 68, 245-249.	1.8	27
194	Platelet-Inhibiting Drugs in the Prevention of Clinical Thrombotic Disease. <i>New England Journal of Medicine</i> , 1975, 293, 1236-1240.	13.9	26
195	Diagnosis of pulmonary embolism. <i>Journal of the American College of Cardiology</i> , 1986, 8, 128B-136B.	1.2	26
196	Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1001-1007.	1.2	26
197	Diagnosis and Treatment of Venous Thromboembolism. <i>Annual Review of Medicine</i> , 2002, 53, 15-33.	5.0	26
198	Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1049-1057.	1.8	26

#	ARTICLE	IF	CITATIONS
199	Comparative value of tests for the diagnosis of venous thrombosis. <i>World Journal of Surgery</i> , 1978, 2, 27-34.	0.8	25
200	Clinical Use of Low Molecular Weight Heparins and Heparinoids. <i>Seminars in Thrombosis and Hemostasis</i> , 1988, 14, 116-125.	1.5	25
201	Rationale for development of low-molecular-weight heparins and their clinical potential in the prevention of postoperative venous thrombosis. <i>American Journal of Surgery</i> , 1991, 161, 512-518.	0.9	25
202	Effect of Streptokinase on Hemostasis. <i>Blood</i> , 1968, 32, 726-737.	0.6	24
203	Reduction in Mortality following Elective Major Hip and Knee Surgery: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 668-674.	1.8	24
204	Treatment of Venous Thromboembolism. <i>Chest</i> , 1986, 89, 426S-433S.	0.4	23
205	Diagnosis of venous thrombosis and pulmonary embolism. <i>American Journal of Cardiology</i> , 1990, 65, C45-C49.	0.7	23
206	Principles and practice of coronary thrombolysis and conjunctive treatment. <i>American Journal of Cardiology</i> , 1991, 68, 382-388.	0.7	23
207	Antithrombotic therapy in deep vein thrombosis and pulmonary embolism. <i>American Heart Journal</i> , 1992, 123, 1115-1122.	1.2	23
208	Familial Thrombophilia: A Review Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1996, 2, 227-236.	0.7	23
209	Hypersulfated Low Molecular Weight Heparin with Reduced Affinity for Antithrombin Acts as an Anticoagulant by Inhibiting Intrinsic Tenase and Prothrombinase. <i>Journal of Biological Chemistry</i> , 2001, 276, 9755-9761.	1.6	23
210	Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?â€”A Systematic Review. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1323-1329.	1.8	22
211	Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. <i>Translational Research</i> , 1998, 132, 181-185.	2.4	21
212	Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: Results of GUSTO-I. <i>American Heart Journal</i> , 1998, 136, 868-876.	1.2	21
213	Antithrombotic Agents in Coronary Artery Disease. <i>Chest</i> , 1986, 89, 54S-67S.	0.4	20
214	Special Report: A Simple System for the Derivation of International Normalized Ratios for the Reporting of Prothrombin Time Results with North American Thromboplastin Reagents. <i>American Journal of Clinical Pathology</i> , 1989, 92, 124-126.	0.4	20
215	Treatment of Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 1999, 82, 870-877.	1.8	19
216	The development and validation of an instrument to measure the quality of health research reports in the lay media. <i>BMC Public Health</i> , 2017, 17, 343.	1.2	19

#	ARTICLE	IF	CITATIONS
217	Pulmonary Embolism in the Elderly. <i>Cardiology Clinics</i> , 1991, 9, 457-474.	0.9	17
218	Fifty years of research on antithrombotic therapy: Achievements and disappointments. <i>European Journal of Internal Medicine</i> , 2019, 70, 1-7.	1.0	17
219	125I-Labeled Fibrinogen Scanning. <i>JAMA - Journal of the American Medical Association</i> , 1975, 233, 970.	3.8	16
220	Effectiveness of Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 1986, 12, 21-37.	1.5	16
221	The emerging role of low-molecular-weight heparin in cardiovascular medicine. <i>Progress in Cardiovascular Diseases</i> , 2000, 42, 235-246.	1.6	16
222	Heparin resistance in acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 23, 93-100.	1.0	15
223	Timing the First Postoperative Dose of Anticoagulants. <i>Chest</i> , 2015, 148, 587-595.	0.4	15
224	Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. <i>Transfusion Medicine Reviews</i> , 2016, 30, 25-29.	0.9	15
225	Guidelines for anticoagulant use in acute coronary syndromes. <i>Lancet, The</i> , 2008, 371, 1559-1561.	6.3	14
226	Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation. <i>TH Open</i> , 2018, 02, e190-e201.	0.7	14
227	Dose Antiplatelet Agents; The Relationship Among Side Effects, and Antithrombotic Effectiveness. <i>Chest</i> , 1986, 89, 4S-10S.	0.4	13
228	Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 944-950.e3.	0.4	13
229	Aspirin response variability after major orthopedic surgery. <i>Thrombosis Research</i> , 2012, 130, 216-220.	0.8	13
230	Oral Anticoagulants. <i>Chest</i> , 1992, 102, 312S-326S.	0.4	12
231	Antithrombin-heparin covalent complex reduces microemboli during cardiopulmonary bypass in a pig model. <i>Blood</i> , 2010, 116, 5716-5723.	0.6	11
232	Contribution of Red Blood Cells to the Saturable Mechanism of Heparin Clearance. <i>Thrombosis and Haemostasis</i> , 1990, 64, 559-563.	1.8	11
233	Antiplatelet drugs in thromboembolism. <i>Postgraduate Medicine</i> , 1979, 66, 119-127.	0.9	10
234	10 Anticoagulant therapy in venous thromboembolism. <i>Best Practice and Research: Clinical Haematology</i> , 1990, 3, 685-692.	1.1	10

#	ARTICLE	IF	CITATIONS
235	Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides. <i>Thrombosis and Haemostasis</i> , 2014, 111, 10-13.	1.8	10
236	Standard and Low Molecular Weight Heparin Have no Effect on Tissue Plasminogen Activator Induced Plasma Clot Lysis or Fibrinogenolysis. <i>Thrombosis and Haemostasis</i> , 1991, 65, 541-544.	1.8	10
237	Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: Results of the VITAL study (Vasoflux International) <i>TJ ETQq1 1 0.784314 rgBT /Øverlock</i>		
238	Clinical Efficacy of Heparin Fractions: Issues and Answers. <i>CRC Critical Reviews in Clinical Laboratory Sciences</i> , 1986, 23, 77-94.	1.0	8
239	In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1895-1901.	1.8	8
240	Sample Size in the Planning and Interpretation of Clinical Trials. <i>Thrombosis and Haemostasis</i> , 1987, 58, 953-956.	1.8	8
241	Venous Thromboembolism: Diagnosis, Treatment, Prevention. <i>Hospital Practice (1995)</i> , 1975, 10, 53-62.	0.5	7
242	In vivo Effects of Low Molecular Weight Heparins on Experimental Thrombosis and Bleeding. Pathophysiology of Haemostasis and Thrombosis: <i>International Journal on Haemostasis and Thrombosis Research</i> , 1986, 16, 82-86.	0.5	7
243	Edoxaban for the Treatment of Venous Thromboembolism in Patients with Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 673-674.	13.9	7
244	Inflammation as a Mechanism and Therapeutic Target in Peripheral Artery Disease. <i>Canadian Journal of Cardiology</i> , 2022, 38, 588-600.	0.8	7
245	Optimal Dosage Regimens of Tissue-Type Plasminogen Activator. <i>Seminars in Thrombosis and Hemostasis</i> , 1987, 13, 160-162.	1.5	6
246	Comparative effects of heparin and LMW heparin on hemostasis. <i>Thrombosis Research</i> , 1991, 61, 11-17.	0.8	6
247	Low-Molecular-Weight Heparin for the Out-of-Hospital Treatment of Venous Thrombosis: Rationale and Clinical Results. <i>Seminars in Thrombosis and Hemostasis</i> , 1997, 23, 77-81.	1.5	6
248	Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2906-2907.	1.2	6
249	The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate. <i>Thrombosis and Haemostasis</i> , 1993, 70, 443-447.	1.8	6
250	Increased Platelet Destruction. <i>Seminars in Thrombosis and Hemostasis</i> , 1982, 8, 75-82.	1.5	5
251	Use of plasminogen activators in venous thrombosis. <i>World Journal of Surgery</i> , 1990, 14, 688-693.	0.8	5
252	Quantifying immature platelets as markers of increased platelet production after coronary artery bypass grafting surgery. <i>European Journal of Haematology</i> , 2018, 101, 362-367.	1.1	5

#	ARTICLE	IF	CITATIONS
253	Prophylaxis and Therapy of Venous Thromboembolism. CRC Critical Reviews in Clinical Laboratory Sciences, 1979, 10, 247-274.	1.0	4
254	The Diagnosis of Clinically Suspected Pulmonary Embolism. Chest, 1986, 89, 417S-425S.	0.4	4
255	Relationship Between Dose, Anticoagulant Effect and the Clinical Efficacy and Safety of Heparin. Advances in Experimental Medicine and Biology, 1992, 313, 283-295.	0.8	4
256	Fixed-Dose, Weight-Adjusted, Unfractionated Heparin (UFH) Given Subcutaneously (sc) without Laboratory Monitoring for Acute Treatment of Venous Thromboembolism (VTE): Randomized Comparison with Low-Molecular-Weight-Heparin (LMWH).. Blood, 2004, 104, 707-707.	0.6	4
257	Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study. TH Open, 2022, 06, e10-e17.	0.7	4
258	4 Clinical potential of low molecular weight heparins. Best Practice and Research: Clinical Haematology, 1990, 3, 545-554.	1.1	3
259	Deep Vein Thrombosis Prophylaxis: Response. Chest, 2009, 136, 1700-1701.	0.4	3
260	Solving the mystery of excessive warfarin-induced bleeding: A personal historical perspective. Thrombosis and Haemostasis, 2014, 112, 853-856.	1.8	3
261	Developing a novel antithrombotic in the academic environment. Seminars in Hematology, 2001, 38, 4-11.	1.8	2
262	Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada. Journal of Thrombosis and Thrombolysis, 2018, 46, 310-315.	1.0	2
263	Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?. TH Open, 2021, 05, e84-e88.	0.7	2
264	Bleeding in Patients with Atrial Fibrillation Treated with Different Doses of Direct Oral Anticoagulants and Vitamin K Antagonists: A Population-Based Study. Blood, 2016, 128, 2617-2617.	0.6	2
265	Clinical Utility of Impedance Plethysmography in the Diagnosis of Recurrent Deep-Vein Thrombosis. Archives of Internal Medicine, 1988, 148, 519.	4.3	1
266	Aspirin and Other Platelet Active Drugs. Chest, 1989, 95, 12S-18S.	0.4	1
267	New Antithrombotics for the Treatment of Acute and Chronic Arterial Ischemia. Vascular Medicine, 1996, 1, 72-78.	0.8	1
268	Antithrombotic drugs for thromboembolic disorders: A lesson in evidence-based medicine. American Journal of Health-System Pharmacy, 1997, 54, 1992-1994.	0.5	1
269	Low-Molecular-Weight Heparin for Anticoagulation During Continuous Venovenous Hemofiltrationâ€”Reply. Archives of Internal Medicine, 2003, 163, 981.	4.3	1
270	Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety?. Future Cardiology, 2021, 17, 175-182.	0.5	1

#	ARTICLE	IF	CITATIONS
271	Practical Application of ¹²⁵ I-Fibrinogen Leg Scanning. CRC Critical Reviews in Clinical Laboratory Sciences, 1981, 14, 241-255.	1.0	0
272	Oral Anticoagulant Therapy Recommendations. Chest, 1994, 105, 328.	0.4	0
273	Is There a Relationship Between the Intensity of Heparin Treatment and Recurrent Thromboembolism?. Clinical and Applied Thrombosis/Hemostasis, 1997, 3, S64-S67.	0.7	0
274	Low-Molecular-Weight Heparin Should Replace Unfractionated Heparin for Treatment of Venous Thrombosis and Unstable Angina. , 1997, 4, 349-351.		0
275	Antithrombotic Therapy. , 2012, , 171-177.		0
276	Small dose subcutaneous heparin in preventing deep venous thrombosis. , 1975, , 233-242.		0
277	Significance: Clinical or Statistical?-Rebuttal. Thrombosis and Haemostasis, 1989, 61, 325-325.	1.8	0
278	Letter by de Vries et al Regarding Article "Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis". Circulation: Cardiovascular Quality and Outcomes, 2022, , 101161CIRCOUTCOMES122008982.	0.9	0